Login

Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Antibodies » Abs to Peptides » Anti -Vasoactive intestinal Polypeptide Receptor 2 (VIP Receptor 2, VIP2R, VIPR2, Helodermin Preferring VIP Receptor, Helodermin-preferring VIP Receptor, Pituitary Adenylate Cyclase Activating Polypeptide Type III Receptor, PACAP Type III Receptor, VPAC2, VPAC2

Anti -Vasoactive intestinal Polypeptide Receptor 2 (VIP Receptor 2, VIP2R, VIPR2,
Helodermin Preferring VIP Receptor, Helodermin-preferring VIP Receptor, Pituitary
Adenylate Cyclase Activating Polypeptide Type III Receptor, PACAP Type III Receptor,
VPAC2, VPAC2

Pricing

  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.

Specifications

Clone Host Grade Applications
Polyclonal Rabbit Affinity Purified E B
Vasoactive intestinal peptide (VIP) is a 28-aminoacid peptide (human, chr 6q26-q27). Expressed and secreted by neurons innervating primary and secondary immune organs such as lymph nodes with a Mol.wt of 20kD. VIP is a potent neurotrophic factor causes vasodilation, lowers arterial blood pressure, and relaxes the smooth muscle of trachea, stomach and gall bladder. VIP also modulates several T-lymphocyte activities including motility, cytokine production, proliferation and apoptosis, VIP exerts its biological activity by binding to two closely related class II G-protein-coupled receptors VPAC-1 and VPAC-2 beside this VIP has its own receptors VIPR1&2 (Vasoactive Intestinal Polypeptide Receptor 1&2) and VIPRRP (VIP receptor-gene repressor protein). VIP shows similarities to glucagon, secretin and gastric inhibitory peptide (GIP) as such it has been considered a member of the glucagon-secretin family. The VIP is 100% conserved in mouse, rat and human. VIP is considered to be a viable candidate for the development of treatments for rheumatoid arthritis, since treatment with VIP significantly reduced incidence of severity of arthritis, the therapeutic effect of VIP was associated with downregulation of both inflammatory and autoimmune components of the disease.
VIPR2, a 438aa (chr.7q36.3) protein in human (437aa in rat and mouse). The VIP receptor2 is also termed as type III PACAP receptor, mainly expressed in neural tissues. This is a receptor for VIP as well as PACAP 38 and 27, G proteins mediate the activity of this receptor, which activates adenyl cyclase and can be coupled to phospholipase C. It shows 86% sequence homology with rat VIPR2.
Catalog #V2115-26C
ApplicationsSuitable for use in ELISA and Western Blot. Other applications not tested.
Recommended DilutionELISA: 0.5-1ug/ml; Control peptide can be used to coat ELISA plates at 1ug/ml. See V2115-26B.
Western Blot: 1-10ug/ml; Using ECL technique.
Optimal dilutions to be determined by the researcher.
Storage and StabilityLyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O or PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Clone TypePolyclonal
IsotypeIgG
HostRabbit
SourceRat
ConcentrationAs reported
FormSupplied as a lyophilized powder from PBS, 0.05% sodium azide.
PurityPurified by immunoaffinity chromatography.
Immunogen19aa peptide from rat VIPR2. Location
SpecificityRecognizes rat Vasoactive Intestinal Peptide Receptor 2.
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.


External Links